RESPONSE TO IMATINIB MESYLATE IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE DISEASES WITH REARRANGEMENTS OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA